SCHEMBL3255485

SCHEMBL3255485

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)Nc4ccccc4OC)cc3c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
LMNA P02545 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 2/20 0.47
HTT P42858 2/20 0.47
HPGD P15428 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KDM4E B2RXH2 3/20 0.45
MAPT P10636 3/20 0.45
HSD17B10 Q99714 2/20 0.44
THRB P10828 1/20 0.44
KMT2A Q03164 3/20 0.44
TSHR P16473 1/20 0.44
POLB P06746 3/20 0.44
OGT O15294 1/20 0.44
MEN1 O00255 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
GAA P10253 2/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3254872 0.91 TDP1 (0.51) ALDH1A1LMNASMN1; SMN2TP53HTT
SCHEMBL3252252 0.89 KMT2A (0.51) ALDH1A1LMNASMN1; SMN2HTTKDM4E
SCHEMBL3249397 0.88 ALDH1A1 (0.44) ALDH1A1LMNASMN1; SMN2TP53HTT
SCHEMBL3254789 0.87 PKM (0.51) ALDH1A1LMNASMN1; SMN2TP53HPGD
SCHEMBL3251813 0.86 POLB (0.47) ALDH1A1LMNASMN1; SMN2TP53HTT
SCHEMBL3250340 0.86 ALDH1A1 (0.55) ALDH1A1LMNASMN1; SMN2TP53HPGD
SCHEMBL3250191 0.85 POLB (0.47) ALDH1A1LMNATP53HTTHPGD
SCHEMBL3250865 0.85 HSD17B10 (0.50) ALDH1A1LMNASMN1; SMN2TP53HTT
SCHEMBL3248963 0.84 TAS2R14 (0.44) ALDH1A1LMNATP53HPGDL3MBTL1
SCHEMBL3244722 0.84 PKM (0.56) ALDH1A1LMNASMN1; SMN2TP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 ALDH1A1 3830/4885LMNA 3096/4885SMN1; SMN2 2559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.